These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 8614505)

  • 1. d-Cycloserine enhances implicit memory in Alzheimer patients.
    Schwartz BL; Hashtroudi S; Herting RL; Schwartz P; Deutsch SI
    Neurology; 1996 Feb; 46(2):420-4. PubMed ID: 8614505
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improved cognition in Alzheimer's disease with short-term D-cycloserine treatment.
    Tsai GE; Falk WE; Gunther J; Coyle JT
    Am J Psychiatry; 1999 Mar; 156(3):467-9. PubMed ID: 10080566
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of cycloserine in the treatment of Alzheimer's disease.
    Fakouhi TD; Jhee SS; Sramek JJ; Benes C; Schwartz P; Hantsburger G; Herting R; Swabb EA; Cutler NR
    J Geriatr Psychiatry Neurol; 1995 Oct; 8(4):226-30. PubMed ID: 8561836
    [TBL] [Abstract][Full Text] [Related]  

  • 4. D-cycloserine treatment of Alzheimer disease.
    Randolph C; Roberts JW; Tierney MC; Bravi D; Mouradian MM; Chase TN
    Alzheimer Dis Assoc Disord; 1994; 8(3):198-205. PubMed ID: 7986489
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cognitive and quantified electroencephalographic correlates of cycloserine treatment in Alzheimer's disease.
    Mohr E; Knott V; Sampson M; Wesnes K; Herting R; Mendis T
    Clin Neuropharmacol; 1995 Feb; 18(1):28-38. PubMed ID: 8665532
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A preliminary study of D-cycloserine treatment in Alzheimer's disease.
    Tsai GE; Falk WE; Gunther J
    J Neuropsychiatry Clin Neurosci; 1998; 10(2):224-6. PubMed ID: 9608414
    [TBL] [Abstract][Full Text] [Related]  

  • 7. D-cycloserine increases positive symptoms in chronic schizophrenic patients when administered in addition to antipsychotics: a double-blind, parallel, placebo-controlled study.
    van Berckel BN; Evenblij CN; van Loon BJ; Maas MF; van der Geld MA; Wynne HJ; van Ree JM; Kahn RS
    Neuropsychopharmacology; 1999 Aug; 21(2):203-10. PubMed ID: 10432468
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments.
    Buchanan RW; Javitt DC; Marder SR; Schooler NR; Gold JM; McMahon RP; Heresco-Levy U; Carpenter WT
    Am J Psychiatry; 2007 Oct; 164(10):1593-602. PubMed ID: 17898352
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Augmentation of behavior therapy with D-cycloserine for obsessive-compulsive disorder.
    Wilhelm S; Buhlmann U; Tolin DF; Meunier SA; Pearlson GD; Reese HE; Cannistraro P; Jenike MA; Rauch SL
    Am J Psychiatry; 2008 Mar; 165(3):335-41; quiz 409. PubMed ID: 18245177
    [TBL] [Abstract][Full Text] [Related]  

  • 10. D-cycloserine facilitation of cognitive behavioral therapy for delusions in schizophrenia.
    Gottlieb JD; Cather C; Shanahan M; Creedon T; Macklin EA; Goff DC
    Schizophr Res; 2011 Sep; 131(1-3):69-74. PubMed ID: 21723096
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Augmentation of exposure therapy with D-cycloserine for social anxiety disorder.
    Hofmann SG; Meuret AE; Smits JA; Simon NM; Pollack MH; Eisenmenger K; Shiekh M; Otto MW
    Arch Gen Psychiatry; 2006 Mar; 63(3):298-304. PubMed ID: 16520435
    [TBL] [Abstract][Full Text] [Related]  

  • 12. D-cycloserine does not enhance exposure-response prevention therapy in obsessive-compulsive disorder.
    Storch EA; Merlo LJ; Bengtson M; Murphy TK; Lewis MH; Yang MC; Jacob ML; Larson M; Hirsh A; Fernandez M; Geffken GR; Goodman WK
    Int Clin Psychopharmacol; 2007 Jul; 22(4):230-7. PubMed ID: 17519647
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Absence of significant interactive effects of high-dose D-cycloserine and ethanol in healthy human subjects: preliminary insights into ethanol actions at the glycine B site of NMDA glutamate receptors.
    Trevisan L; Petrakis IL; Pittman B; Gueorguieva R; D'Souza DC; Perry E; Limoncelli D; Krystal JH
    Alcohol Clin Exp Res; 2008 Jan; 32(1):36-42. PubMed ID: 18028532
    [TBL] [Abstract][Full Text] [Related]  

  • 14. D-cycloserine for Alzheimer's disease.
    Laake K; Oeksengaard AR
    Cochrane Database Syst Rev; 2002; 2002(2):CD003153. PubMed ID: 12076471
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of NMDA modulation in scopolamine dementia.
    Jones RW; Wesnes KA; Kirby J
    Ann N Y Acad Sci; 1991; 640():241-4. PubMed ID: 1837979
    [TBL] [Abstract][Full Text] [Related]  

  • 16. D-cycloserine, a partial agonist at the glycine site coupled to N-methyl-D-aspartate receptors, improves visual recognition memory in rhesus monkeys.
    Matsuoka N; Aigner TG
    J Pharmacol Exp Ther; 1996 Aug; 278(2):891-7. PubMed ID: 8768744
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Therapeutic Role of d-Cycloserine in Schizophrenia.
    Goff D
    Adv Pharmacol; 2016; 76():39-66. PubMed ID: 27288073
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pilot-controlled trial of D-cycloserine for the treatment of post-traumatic stress disorder.
    Heresco-Levy U; Kremer I; Javitt DC; Goichman R; Reshef A; Blanaru M; Cohen T
    Int J Neuropsychopharmacol; 2002 Dec; 5(4):301-7. PubMed ID: 12466030
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The NMDA receptor partial agonist d-cycloserine does not enhance motor learning.
    Günthner J; Scholl J; Favaron E; Harmer CJ; Johansen-Berg H; Reinecke A
    J Psychopharmacol; 2016 Oct; 30(10):994-9. PubMed ID: 27436230
    [TBL] [Abstract][Full Text] [Related]  

  • 20. d-Cycloserine administration does not affect neurocognition in concurrent cocaine- and nicotine-dependent volunteers.
    Kalechstein AD; Yoon JH; Mahoney JJ; Newton TF; Chang L; De La Garza R
    Pharmacol Biochem Behav; 2012 Dec; 103(2):403-7. PubMed ID: 22960612
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.